Infensa scientists publish in European Heart Journal showing efficacy of lead drug candidate when administered at relevant timepoints in preclinical models of moderate and severe myocardial infarction

Previous
Previous

Brisbane startup Infensa spins medical miracle from spider venom

Next
Next

Infensa CEO Mark Smythe received the LSQ McCullough Robertson Industry Excellence Award from Life Sciences Queensland in recognition of his major contributions to the Queensland life sciences industry